Christopher Muntz - Contracting Officer / Team Lead

Christopher Muntz serves as a Contracting Officer and Team Lead within the Administration for Strategic Preparedness and Response (ASPR), where he plays a pivotal role in securing critical biomedical capabilities to support national health emergency preparedness. He manages the full lifecycle of acquisitions for research and development contracts focused on medical countermeasures, diagnostic platforms, and advanced biotechnology solutions. His work directly enables ASPR’s mission to sustain a resilient biomedical industrial base capable of rapid response to pandemics, chemical threats, and biological incidents, ensuring timely access to innovative, high-priority health security assets. Muntz collaborates extensively with a diverse ecosystem of research institutions, biotech firms, and contract research organizations engaged in preclinical and clinical development of therapeutics, vaccines, and diagnostic tools. While no single contractor dominates his portfolio, his procurement patterns reflect consistent engagement with entities possessing specialized expertise in molecular biology, biocontainment, and scalable manufacturing processes. He fosters collaborative, performance-driven relationships with vendors who demonstrate technical agility and regulatory compliance under urgent timelines. Muntz’s contracting approach reflects a strong preference for full and open competition, with 100% of his acquisitions conducted without set-asides for 8(a), HUBZone, SDVOSB, or other socioeconomic categories. This reflects the urgent, mission-critical nature of ASPR’s objectives, where technical capability and speed of delivery take precedence over socioeconomic preferences, though small businesses remain eligible and actively compete under open solicitations. His primary focus is on NAICS 541714—Research and Development in Biotechnology—where he procures advanced R&D services spanning protein engineering, nucleic acid therapeutics, high-throughput screening, and biosafety level 3/4 platform development. His expertise lies in navigating complex regulatory pathways and ensuring acquisitions align with FDA and CDC standards for emergency use authorization and public health deployment.